GW4064: Selective Non-Steroidal FXR Agonist in Metabolic Research

Executive Summary: GW4064 is a potent, non-steroidal FXR agonist with an EC50 of 15 nM in isolated receptor assays and 90 nM in human FXR-transfected cells (APExBIO). Its selective activation of FXR modulates bile acid, cholesterol, and triglyceride regulation, supporting studies of metabolic disorders (Zhou et al., 2025). GW4064 has demonstrated efficacy in reducing serum triglycerides and very low-density lipoprotein (VLDL) in rodent models. Despite its utility, GW4064 displays poor aqueous and ethanol solubility, UV instability, and a stilbene pharmacophore linked to potential toxicity, restricting its use to research settings. As a benchmark FXR tool compound, it is critical for studies on FXR signaling and metabolic pathway modulation.

Biological Rationale

The farnesoid X receptor (FXR, NR1H4) is a nuclear hormone receptor expressed predominantly in the liver, intestine, and kidney. FXR regulates bile acid synthesis, lipid homeostasis, and glucose metabolism (Zhou et al., 2025). FXR activation suppresses bile acid synthesis via negative feedback on CYP7A1 and modulates genes involved in triglyceride and cholesterol metabolism. Dysregulation of FXR signaling is implicated in metabolic disorders, including non-alcoholic fatty liver disease, cholestasis, and fibrosis. GW4064, by selectively activating FXR, provides a precise tool to dissect these regulatory networks in both in vitro and in vivo models. Its specificity enables the decoupling of FXR-mediated effects from other nuclear receptors, addressing key questions in metabolic disorder research (see also; this article extends the mechanistic evidence base with new fibrotic disease data).

Mechanism of Action of GW4064

GW4064 is a synthetic, non-steroidal agonist that binds directly to the ligand-binding domain of FXR. Upon binding, GW4064 induces conformational changes facilitating recruitment of coactivators and transcriptional complexes, driving the expression of FXR target genes (e.g., SHP, BSEP, SREBP-1c, FGF19 in humans). FXR activation by GW4064 represses the TLR4 pathway and enhances ferroptosis features, thereby modulating inflammation and fibrosis, as demonstrated in LX-2 hepatic stellate cells challenged with nickel oxide nanoparticles (Zhou et al., 2025). The compound is chemically defined as 3-[(E)-2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]ethenyl]benzoic acid (C28H22Cl3NO4, MW 542.85). It is insoluble in water and ethanol but dissolves in DMSO ≥24.7 mg/mL (APExBIO).

Evidence & Benchmarks

• GW4064 activates FXR with an EC50 of 15 nM in isolated receptor assays and 90 nM in human FXR-transfected cells (APExBIO).
• In LX-2 cells, GW4064 treatment suppresses TLR4 expression and alleviates nickel oxide nanoparticle-induced collagen deposition, confirming FXR's regulatory role in fibrosis (Zhou et al. 2025, DOI).
• GW4064 reduces serum triglyceride and VLDL secretion in KK-Ay, ob/ob, and SHP+/+ mouse models, supporting its use in studies of lipid metabolism modulation (GSKChem).
• GW4064 is a reference tool for dissecting the FXR/TLR4/ferroptosis axis in metabolic and fibrotic disease models, as reviewed in advanced mechanistic articles (GSK1363089).
• Optimal use requires DMSO-based formulation due to insolubility in water and ethanol, and short-term storage at -20°C for solution stability (APExBIO).

Applications, Limits & Misconceptions

GW4064 is primarily used as a research tool compound to study FXR function, bile acid metabolism, lipid and glucose regulation, and fibrotic processes. It is not approved for therapeutic use due to physicochemical and toxicological limitations. Its poor aqueous solubility and light sensitivity require precise handling in laboratory workflows. GW4064 is commonly used in cell-based assays, rodent models, and mechanistic studies of FXR signaling pathways. For practical guidance on assay optimization and troubleshooting, see this scenario-based best practices article; the present review augments with updated stability and mechanistic data from recent fibrosis studies.

Common Pitfalls or Misconceptions

• GW4064 is not suitable for in vivo therapeutic development due to its stilbene pharmacophore and associated toxicity risk.
• It is ineffective when dissolved in water or ethanol; only DMSO formulations are recommended for solubility ≥24.7 mg/mL.
• GW4064 solutions are unstable when exposed to UV light or at room temperature for prolonged periods.
• FXR-independent effects should not be assumed; always use appropriate controls to confirm target engagement.
• GW4064 is not a pan-nuclear receptor agonist; its selectivity for FXR distinguishes it from other nuclear hormone receptor modulators.

Workflow Integration & Parameters

For cell-based assays, GW4064 (SKU B1527) should be dissolved in DMSO at concentrations up to 24.7 mg/mL and aliquoted for short-term storage at -20°C (APExBIO). Light protection is mandatory due to UV instability. Recommended working concentrations typically range from 0.01 to 10 μM, depending on cell type and assay conditions. For in vivo studies, formulation in DMSO or other compatible vehicles is essential to ensure bioavailability. Rigorous controls, including FXR-knockout or antagonist co-treatment, are advised to attribute observed effects specifically to FXR activation. For deeper mechanistic insights and emerging applications in ferroptosis and fibrosis, consult recent reviews; this article uniquely highlights the interplay with the FXR/TLR4/ferroptosis axis.

Conclusion & Outlook

GW4064 remains the gold-standard non-steroidal FXR agonist for preclinical studies of bile acid, cholesterol, and triglyceride regulation. Its selective activation of FXR enables precise dissection of metabolic and fibrotic pathways, as validated by multiple peer-reviewed studies (Zhou et al., 2025). Despite formulation and stability challenges, GW4064 (as supplied by APExBIO) continues to drive advances in metabolic disorder research and mechanistic understanding of FXR signaling. Ongoing development of more drug-like FXR agonists will leverage the foundational insights provided by GW4064-driven studies.